Sagimet Biosciences Inc
NASDAQ:SGMT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.47
18.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SGMT stock under the Base Case scenario is 3.12 USD. Compared to the current market price of 4.76 USD, Sagimet Biosciences Inc is Overvalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sagimet Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SGMT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Sagimet Biosciences Inc
Balance Sheet Decomposition
Sagimet Biosciences Inc
Current Assets | 157.2m |
Cash & Short-Term Investments | 152.5m |
Other Current Assets | 4.7m |
Non-Current Assets | 17.6m |
Long-Term Investments | 17.5m |
PP&E | 114k |
Current Liabilities | 4.1m |
Accounts Payable | 1.2m |
Accrued Liabilities | 2.9m |
Other Current Liabilities | 11k |
Earnings Waterfall
Sagimet Biosciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-26.4m
USD
|
Operating Income
|
-26.4m
USD
|
Other Expenses
|
3.6m
USD
|
Net Income
|
-22.8m
USD
|
Free Cash Flow Analysis
Sagimet Biosciences Inc
USD | |
Free Cash Flow | USD |
SGMT Profitability Score
Profitability Due Diligence
Sagimet Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Sagimet Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
SGMT Solvency Score
Solvency Due Diligence
Sagimet Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Sagimet Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SGMT Price Targets Summary
Sagimet Biosciences Inc
According to Wall Street analysts, the average 1-year price target for SGMT is 33.25 USD with a low forecast of 6.06 USD and a high forecast of 70.35 USD.
Dividends
Current shareholder yield for SGMT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SGMT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sagimet Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). In addition to NASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase II clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
Contact
IPO
Employees
Officers
The intrinsic value of one SGMT stock under the Base Case scenario is 3.12 USD.
Compared to the current market price of 4.76 USD, Sagimet Biosciences Inc is Overvalued by 34%.